SO

Sergio Occhipinti

CEO at NIB biotec

Sergio Occhipinti has a diverse work experience in various roles and organizations. Sergio started their career as a Borsista at the University of Turin in 2009. From 2010 to 2013, they worked as a PHD Student at the same university. Following this, they joined the Fondazione Umberto Veronesi as a Postdoctoral Fellow from 2014 to 2015. Concurrently, they also worked as a Postdoctoral Researcher at the University of Turin from 2014, with specific roles including Postdoctoral fellow, Postdoctoral Researcher, and eventually as a PhD candidate. In 2015, they joined AOU Città della salute e della scienza di Torino in a role related to educational coordination. In 2017, they became the CEO of NIB biotec. Finally, they returned to the Fondazione Umberto Veronesi in 2018 as a Postdoctoral Researcher, where they worked until February 2022.

Sergio Occhipinti's education history starts in 2002 when they enrolled at the Università degli Studi di Torino to pursue a degree in Biotecnologie mediche. Sergio completed their laura magistrale in that field in 2008. In the following year, Sergio Occhipinti continued their education at the same university and obtained a Laurea Magistrale LM in Biotecnologie in 2009. Later, in 2017, they returned to the Università degli Studi di Torino to pursue a Master's degree in Progettazione e Management del Multimedia per la Comunicazione. This program lasted until 2018. The provided information does not indicate if Sergio Occhipinti completed the Master's program or obtained any specific degree in that field.

Location

Turin, Italy

Links

Previous companies


Org chart

No direct reports

Teams

This person is not in any teams


Offices


NIB biotec

NIB biotec identifies the combination of molecules differently expressed in the urine of healthy subjects and patients with prostate cancer at first diagnosis. They provide ScreeNIB tests, MRI, and invasive tests, such as prostate biopsy services. The ScreeNIB test evaluates the presence of two molecules in the urine and returns a probability ofhaving prostate cancer and therefore the need to carry out more in-depth diagnostic tests.


Headquarters

Turin, Italy

Employees

1-10

Links